CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RN
The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
This content originally appeared on our sister site,
OncLive spoke with Kelly Garvin, MA, BSN, RN, Moffitt Cancer Center, about the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.
Five FDA-approved CAR T-cell products are currently available for patients with certain hematologic malignancies, with even more indications expected in the future. For most patients with diffuse large B-cell lymphoma, treatment with immunotherapy and the chemotherapy regimen comprised of rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone can be curative; however, outcomes remain poor for those who do not respond to this approach, according to Garvin.
Currently, ongoing trials are examining CAR T-cell therapy vs standard of care in this patient population, to see whether the former modality can yield better outcomes, Garvin notes. If patients with poor prognostic factors can be identified early enough to utilize CAR T-cell therapy, outcomes could potentially be improved, Garvin concludes.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025